Results 21 to 30 of about 8,118 (201)
Antithyroid drugs in Graves′ disease: Are we stretching it too far?
Indian Journal of Endocrinology and Metabolism, 2016 Introduction: Early and durable achievement of euthyroid or hypothyroid status with low likelihood of relapse is the key to effective treatment of Graves′ disease (GD).
Muthukrishnan Jayaraman +2 more
doaj +2 more sources
Antithyroid Drug-induced Agranulocytosis
Journal of the Chinese Medical Association, 2009 Antithyroid drugs are widely used to treat hyperthyroidism, especially Graves' disease, but they tend to cause agranulocytosis, which increases the mortality rate. Granulocyte colony-stimulating factor decreases the duration of recovery from agranulocytosis.
Sun, Ming-Tsung +2 more
openaire +3 more sources
Exposure to antithyroid drugs and ethylenethiourea and risk of thyroid cancer: a systematic review of the epidemiologic evidence. [PDF]
Eur J Cancer Prev, 2022 Introduction: The thyroid peroxidase inhibiting compounds methimazole, methylthiouracil, propylthiouracil, thiouracil (i.e. 'antithyroid' drugs) and ethylenethiourea have been associated to thyroid tumours in rodents.
La Vecchia C, Turati F, Negri E.
europepmc +2 more sources
Antithyroid activity of some 6-(alkylsulfanyl)-9H-purines [PDF]
Journal of the Serbian Chemical Society, 2011 Some alkyl and aryl derivatives of 9H-purine-6-thiol were synthesized and evaluated in vitro and in vivo for potential antithyroid effects. Spectrophotometric studies demonstrated 1:1 charge transfer complexation between iodine and these compounds ...
Khan Mibahul A. +5 more
doaj +2 more sources
A short review of current knowledge regarding long-term treatment of Graves' disease with antithyroid drugs. [PDF]
Hormones (Athens)Graves' disease is the most common form of hyperthyroidism, especially in younger people. Current European guidelines recommend antithyroid drugs as initial treatment for a period limited to 12-18 months.
Giordani I, Sykiotis GP.
europepmc +2 more sources
Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs. [PDF]
Int J Endocrinol, 2023 Objective. To study the risk factors for granulocytopenia caused by antithyroid drugs. Methods. Patients who were diagnosed with Graves’ hyperthyroidism and regularly treated with antithyroid drugs (ATDs) from January 2010 to July 2022 at Nanjing Drum ...
Li J, Zhang X, Li L, Zhu Q, Ge W, Ji C.
europepmc +2 more sources
Endocrine Regulations, 2017 Objective. Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenic purpura, neurologic abnormalities, fever, and renal insufficiency.
Tazegul G +9 more
doaj +2 more sources
Clinical pharmacology of thyroid and antithyroid drugs [PDF]
Arhiv za farmaciju, 2022 Autoimmune diseases accompanied by the development of hypothyroidism (Hashimoto's thyroiditis) and hyperthyroidism (Graves' disease) are one of the most common disorders of the thyroid gland.
Stepanović-Petrović Radica +1 more
doaj +1 more source
The Effect of Thyrotropin-Releasing Hormone and Antithyroid Drugs on Fetal Thyroid Function. [PDF]
Children (Basel), 2021 A euthyroid pregnant woman will normally have a fetus that displays normal fetal development. However, studies have long demonstrated the role of T3 (Triiodothyronine), T4 (Thyroxine), and TSH (Thyroid Stimulating Hormone) and their degree of ...
Vrachnis N +8 more
europepmc +3 more sources